Genetic Cancer Biomarker

Genetic Cancer Biomarker

Genetic cancer biomarkers are specific changes in DNA that can indicate an increased risk of developing cancer or predict how a particular cancer might behave. These biomarkers play a crucial role in early detection, personalized treatment plans, and assessing prognosis by identifying genetic mutations or alterations associated with different types of cancer. Several other factors, such as rising genetic disorders and unhealthy lifestyles are leading drivers of genetic cancer biomarkers globally. For instance, according to the BMC Public Health, in July 2023, the prevalence of unhealthy lifestyles was 86.4% for diet, 14.5% for alcohol, 6.0% for tobacco, 72.2% for physical activity, 42.3% for screen time, and 63.9% for sleep duration.

The Genetic Cancer Biomarker Market is expected to grow at a steady rate of around 18.4% owing to the increased prevalence of alcohol and tobacco globally. According to the 2021 National Survey on Drug Use and Health (NSDUH), 29.5 million people ages 12 and older had Alcohol Use Disorder (AUD) in the year 2020. Several factors, including a surge in the incidence of cancer, increasing awareness regarding throat cancer, increasing smoking population, rising alcoholism culture, and increased investments in oncology departments are driving the growth of the market during the forecast period. Apart from this, accelerated treatment efficiency with genetic cancer biomarkers has resulted in faster treatment procedures and better accuracy which is also driving this market of genetic cancer biomarkers at a steady rate. For instance, according to the American Cancer Society Journals in 2021, 1,898,160 new cancer cases and 608,570 cancer deaths were reported in the U.S.

• Based on cancer type, the market is segmented into breast, prostate, leukemia, and others. The breast cancer segment held the maximum share in the global market of genetic cancer biomarkers in 2022. This segment dominated the market because of the delayed pregnancies, rising cases of obesity, increasing geriatric population, and increased prevalence of ill lifestyles including smoking, alcoholism, and unhealthy lifestyles among people. A family history of breast cancer is also a propelling factor for this segment. For instance, according to the World Health Organization in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. Thus, amongst cancer types, the breast cancer segment held a significant share of the market in 2022.
• Based on technology, the market is categorized into OMICS, bioinformatics, and others. The OMICS segment is expected to hold a significant share of the market in the forecast period owing to its potential feature of providing a huge amount of data in a very short period. OMICS technology focuses on the four big omics, i.e., genomics, transcriptomics, proteomics, and metabolics, and their epiomics. This segment is propelled by rising technological advancements. For instance, in April 2023, Biomodal, formerly known as Cambridge Epigenetix, launched its new duet multiomics solution, which reveals the combinatorial power of genetic and epigenetic information from a single low-volume sample. Thus, amongst technology, the OMICS category is expected to witness higher CAGR during the forecast period.
• For a better understanding of the market adoption of genetic cancer biomarkers, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing smoke pollution, increasing alcohol consumption, and rising number of investments in developing effective genetic cancer biomarkers. Government organizations are initiating throat cancer awareness programs to provide efficient care to patients. For example, In July 2023, the American Association for Cancer Research and the American Head and Neck Society organized the third AACR-AHNS Joint Conference on Head and Neck Cancer in Montreal to present their latest research and provide critical updates on head and neck cancer biology, detection, imaging, prevention, and therapy, among other topics. The AACR also awards research grants to investigators pursuing promising research related to head and neck cancer. Thus, amongst regions, North America held a significant share of the market in 2022.
• Some of the major players operating in the market include F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; QIAGEN N.V.; Illumina Inc.; Bio-Rad Laboratories Inc.; Exact Sciences; Merck KGaA; Pfizer Inc.; Seegene Technologies Inc.; Siemens Healthineers.